title: Outcome of dialysis patients submitted to coronary revascularization.
abstract: Cardiovascular disease accounts for almost half of the total mortality in patients with end stage renal disease (ESRD). It has recently been debated whether coronary revascularization has the same rate of risks and successes in this cohort of patients compared to patients without renal disease. Since 1991, 17 dialysis patients were submitted to coronary revascularization in our center. Seven patients were following peritoneal, 10 hemodialytic treatment. Four patients were submitted to percutaneous transluminal coronary angioplasty (PTCA) and 13 to surgical revascularization (CABG). In 2 patients the coronary lesion was unique, in the others stenosis of multiple vessels were found. Six patients were diabetic. The mean age at the onset of the coronary artery disease (CAD) was 57.17 +/- 11.6 years. The mean time elapsed from the onset of the CAD and the performance of the PTCA or CABG was 30.1 +/- 35.4 months. The mean time from beginning of dialysis treatment to revascularization was 48.2 +/- 39.6 months. Mean hemoglobin values were 9.7 +/- 1 g/dL, mean phosphorus values were 5.2 +/- 8.7 mg/dL, mean cholesterol values were 211 +/- 49.5 mg/dL. The procedure was technically successful in all patients. Mean survival was 25.09 +/- 28.12 months. Twelve patients died, 5 of whom within one month. Survival at one month was 70.5%, at 6 months 58.8%, at one year 52.9%, at 2 years 47%. There was neither significant difference patients submitted to PTCA and those submitted to CABG, nor between diabetic and non-diabetic patients. In conclusion, coronary revascularization in our experience is a high risk procedure in dialysis patients. The reasons for this could be the severe general conditions of these patients affected with diffuse vasculopathy and the long time elapsed since the onset of the ischemic cardiopathy. Thus, our results could suggest the opportunity of performing earlier screening of coronary situation and revascularization treatment in CAD dialysis patients.
authors.affiliation: Department of Nephrology and Cardiology, Giovanni Bosco Hospital, Turin, Italy.
authors.forename: C
authors.initials: C
authors.lastname: Rollino
authors.forename: M
authors.initials: M
authors.lastname: Formica
authors.forename: M
authors.initials: M
authors.lastname: Minelli
authors.forename: R
authors.initials: R
authors.lastname: Boero
authors.forename: G
authors.initials: G
authors.lastname: Beltrame
authors.forename: F
authors.initials: F
authors.lastname: Bonello
authors.forename: A
authors.initials: A
authors.lastname: Pignataro
authors.forename: S
authors.initials: S
authors.lastname: Borsa
authors.forename: F
authors.initials: F
authors.lastname: Quarello
mesh_terms: D017668:Age of Onset; D015906:Angioplasty, Balloon, Coronary; D002784:Cholesterol / Q000097:blood; D001026:Coronary Artery Bypass; D003327:Coronary Disease / Q000150:complications / Q000601:surgery; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications* / Q000401:mortality; D008875:Middle Aged; D010530:Peritoneal Dialysis; D010758:Phosphorus / Q000097:blood; D006435:Renal Dialysis; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D006454:Hemoglobins; D010758:Phosphorus; D002784:Cholesterol